Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
1. Have a diagnosis of histologically or cytologically confirmed peritoneal
mesothelioma, of epithelial, biphasic, or sarcomatoid subtypes
2. Have disease burden amenable to cytoreduction and hyperthermic intraperitoneal
chemotherapy (HIPEC), as determined by a surgeon specializing in mesothelioma
3. Have measurable or evaluable disease based on RECIST 1.1 or on laparoscopy
4. Have no definitive evidence of visceral metastases by best staging
5. Be willing to undergo laparoscopy or mini-laparotomy for peritoneal staging
6. Adequate organ function as determined by screening labs,
7. Have an ECOG performance status of < 2
8. Be 18 years of age on day of signing informed consent
9. Be willing and able to provide written informed consent for the trial
Exclusion Criteria:
1. Is currently participating in a study of an investigational agent and received an
investigational agent within 4 weeks of the first dose of treatment on this protocol
2. Has received any immunotherapy agents outside of this protocol within 4 weeks of the
first dose of treatment on this protocol
3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(>10 mg of prednisone daily or equivalent) or any other form of immunosuppressive
therapy within 14 days prior to the first dose of study drug.
4. Has a known history of active TB infection (Bacillus tuberculosis)
5. Has active COVID-19 infection
6. Has known history of, or any evidence of active, non-infectious pneumonitis that
required steroids, or active pneumonitis
7. Has a severe hypersensitivity to nivolumab or any of its excipients
8. Has a severe hypersensitivity to ipilimumab or any of its excipients
9. Has an active autoimmune disease that has required systemic treatment in the past 2
years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs)
10. Has a known additional malignancy that is progressing or required active treatment
within the 3 years prior to enrollment - exceptions include basal cell carcinoma of
the skin or squamous cell carcinoma of the skin that has undergone potentially
curative therapy or in situ cervical cancer or other tumors that will not affect
life expectancy
11. Has an active infection requiring systemic therapy
12. Has a known history of HIV, Hepatitis B, or Hepatitis C
13. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
14. Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the screening visit through 120 days
after the last dose of trial treatment
1. Female subjects of childbearing potential should have a negative urine or serum
pregnancy within 72 hours prior to receiving the first dose of study
medication. If the urine test is positive or cannot be confirmed as negative, a
serum pregnancy test will be required.
2. Female subjects of childbearing potential should be willing to use 2 methods of
birth control or be surgically sterile, or abstain from heterosexual activity
for the course of the study through 120 days after the last dose of study
medication (Reference Section 5.8.2). Subjects of childbearing potential are
those who have not been surgically sterilized or have not been free from menses
for > 1 year.
3. Male subjects should agree to use an adequate method of contraception starting
with the first dose of study therapy through 120 days after the last dose of
study therapy.
15. Is on anticoagulation that cannot be discontinued in the perioperative period
16. Has received a live vaccine within 30 days of planned start of study therapy
